RxDoctor Payments Data

Stephen Gallo, DO

Vascular Surgery · Springfield, MONPI 1710368725

Payments from drug & device makers

What this record shows

This record is dominated by food and beverage: $3,127 of the $4,504 with a category attached, or 69.4%. 14 manufacturers reported payments, led by W. L. Gore & Associates, Inc. at 35.7% of the total. That places this record below the midpoint for vascular surgery clinicians in MO, where the typical reported total is $6,319.

$4,504in general payments, 2019–2025

Across 69 payments — averaging $65.27 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • W. L. Gore & Associates, Inc.$2K
  • Silk Road Medical, Inc.$1K
  • Medtronic$412
  • Penumbra, Inc.$291
  • Endologix LLC$191
  • Abbott$150
  • plus $649 from 8 others

What the payments were for

  • Travel & lodging$1,37731%
  • Food & beverage$3,12769%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$4,504 in reported general payments places this provider in the 40th percentile of 92 vascular surgery providers in Missouri.

See all vascular surgery providers in Missouri

Medicare billing

Part B allowed, 2024
$80,268
Medicare patients
264
Services billed
514

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
XareltoRivaroxaban19$17,936
EliquisApixaban13$7,996
Icosapent Ethyl12$2,788
Atorvastatin Calcium55$801
ClopidogrelClopidogrel Bisulfate84$774
Cilostazol41$675
Oxycodone Hcl44$134
Oxycodone-AcetaminophenOxycodone Hcl/Acetaminophen16$67
Prednisone14$34

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Johnson & JohnsonXarelto$150$17,93619 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 40th percentile of 92 vascular surgery providers in Missouri.

Other vascular surgery in Springfield

See the full list for Missouri

Where these figures come from

Is this you, or does something look wrong? →